Literature DB >> 32681241

Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC.

Xuanwen Bao1,2, Run Shi3, Tianyu Zhao4,5,6, Yanfang Wang7, Natasa Anastasov8, Michael Rosemann9, Weijia Fang10.   

Abstract

Triple-negative breast cancer (TNBC) is characterized by a more aggressive clinical course with extensive inter- and intra-tumour heterogeneity. Combination of single-cell and bulk tissue transcriptome profiling allows the characterization of tumour heterogeneity and identifies the association of the immune landscape with clinical outcomes. We identified inter- and intra-tumour heterogeneity at a single-cell resolution. Tumour cells shared a high correlation amongst stemness, angiogenesis, and EMT in TNBC. A subset of cells with concurrent high EMT, stemness and angiogenesis was identified at the single-cell level. Amongst tumour-infiltrating immune cells, M2-like tumour-associated macrophages (TAMs) made up the majority of macrophages and displayed immunosuppressive characteristics. CIBERSORT was applied to estimate the abundance of M2-like TAM in bulk tissue transcriptome file from The Cancer Genome Atlas (TCGA). M2-like TAMs were associated with unfavourable prognosis in TNBC patients. A TAM-related gene signature serves as a promising marker for predicting prognosis and response to immunotherapy. Two commonly used machine learning methods, random forest and SVM, were applied to find the genes that were mostly associated with M2-like TAM densities in the gene signature. A neural network-based deep learning framework based on the TAM-related gene signature exhibits high accuracy in predicting the immunotherapy response.

Entities:  

Keywords:  M2-like tumour-associated macrophages (M2-like TAMs); Prognosis; Triple-negative breast cancer (TNBC); Tumour heterogeneity; Tumour-infiltrating immune cells

Mesh:

Substances:

Year:  2020        PMID: 32681241     DOI: 10.1007/s00262-020-02669-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  31 in total

1.  Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.

Authors:  Tao Fan; Yu Liu; Hengchang Liu; Liyu Wang; He Tian; Yujia Zheng; Bo Zheng; Liyan Xue; Fengwei Tan; Qi Xue; Shungeng Gao; Chunxiang Li; Jie He
Journal:  Cancer Immunol Immunother       Date:  2021-05-11       Impact factor: 6.968

Review 2.  Understanding the Transcriptomic Landscape to Drive New Innovations in Musculoskeletal Regenerative Medicine.

Authors:  Stacey M Thomas; Cheryl L Ackert-Bicknell; Michael J Zuscik; Karin A Payne
Journal:  Curr Osteoporos Rep       Date:  2022-02-14       Impact factor: 5.096

3.  ZIM3 activation of CCL25 expression in pulmonary metastatic nodules of osteosarcoma recruits M2 macrophages to promote metastatic growth.

Authors:  Jing Li; Chenguang Zhao; Dong Wang; Shuang Wang; Hui Dong; Difan Wang; Yubing Yang; Jiaxi Li; Feng Cui; Xijing He; Jie Qin
Journal:  Cancer Immunol Immunother       Date:  2022-09-26       Impact factor: 6.630

4.  Immu-Mela: An open resource for exploring immunotherapy-related multidimensional genomic profiles in melanoma.

Authors:  Jing Yang; Shilin Zhao; Jing Wang; Quanhu Sheng; Qi Liu; Yu Shyr
Journal:  J Genet Genomics       Date:  2021-05-14       Impact factor: 4.275

Review 5.  Artificial Intelligence in Bulk and Single-Cell RNA-Sequencing Data to Foster Precision Oncology.

Authors:  Marco Del Giudice; Serena Peirone; Sarah Perrone; Francesca Priante; Fabiola Varese; Elisa Tirtei; Franca Fagioli; Matteo Cereda
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

Review 6.  Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage.

Authors:  James Isaacs; Aaron C Tan; Brent A Hanks; Xiaofei Wang; Kouros Owzar; James E Herndon; Scott J Antonia; Steven Piantadosi; Mustafa Khasraw
Journal:  Clin Cancer Res       Date:  2021-07-26       Impact factor: 12.531

Review 7.  Single-Cell Profiling to Explore Immunological Heterogeneity of Tumor Microenvironment in Breast Cancer.

Authors:  Xiao Yuan; Jinxi Wang; Yixuan Huang; Dangang Shangguan; Peng Zhang
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

8.  Identification of a Transcription Factor Signature That Can Predict Breast Cancer Survival.

Authors:  Chunni Fan; Jianshi Du; Ning Liu
Journal:  Comput Math Methods Med       Date:  2021-02-19       Impact factor: 2.238

9.  PNOC Expressed by B Cells in Cholangiocarcinoma Was Survival Related and LAIR2 Could Be a T Cell Exhaustion Biomarker in Tumor Microenvironment: Characterization of Immune Microenvironment Combining Single-Cell and Bulk Sequencing Technology.

Authors:  Zheng Chen; Mincheng Yu; Jiuliang Yan; Lei Guo; Bo Zhang; Shuang Liu; Jin Lei; Wentao Zhang; Binghai Zhou; Jie Gao; Zhangfu Yang; Xiaoqiang Li; Jian Zhou; Jia Fan; Qinghai Ye; Hui Li; Yongfeng Xu; Yongsheng Xiao
Journal:  Front Immunol       Date:  2021-03-24       Impact factor: 7.561

10.  Protein Tyrosine Kinase 7 Regulates EGFR/Akt Signaling Pathway and Correlates With Malignant Progression in Triple-Negative Breast Cancer.

Authors:  Nai-Peng Cui; Shu Qiao; Shan Jiang; Jin-Lin Hu; Ting-Ting Wang; Wen-Wen Liu; Yan Qin; Ya-Nan Wang; Li-Shuang Zheng; Jin-Chao Zhang; Yong-Ping Ma; Bao-Ping Chen; Jian-Hong Shi
Journal:  Front Oncol       Date:  2021-07-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.